You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Peripheral Neuropathy Articles
Popular Peripheral Neuropathy Articles
Highly Recommended Peripheral Neuropathy Articles
Send a link to this page to your friends and colleagues.
The US Food and Drug Administration has approved US sales of NUCYNTA® ER (tapentadol), a twice-daily extended-release oral analgesic for the treatment of pain from diabetic peripheral neuropathy. The drug, produced by New Jersey-based Janssen Pharmaceuticals, Inc., provides around-the-clock management for moderate to severe chronic neuropathic pain. Janssen says that it is currently the only opioid on the US market that has been approved for treating the condition.
An estimated 8 million people in the United States suffer from diabetic peripheral neuropathy, a condition in which high blood sugar inflames and damages nerves in the extremities—arms, hands, legs, feet, and toes. The most common symptoms are numbness, burning, tingling, or tickling sensations in the affected areas. However, those symptoms often give way to extreme pain.
Treatment for diabetic neuropathy pain can involve the use of several drug agents, including anti-seizure medications, antidepressants, lidocaine topical patches, and opioids used to treat pain in general. All drugs used to treat the condition have side effects, the most common being dizziness and drowsiness. Janssen states that most common adverse reactions reported by patients treated with NUCYNTA ER were nausea, constipation, vomiting, dizziness, headache, and sleepiness.
Because the active ingredient in NUCYNTA® ER, tapentadol, is classified as a controlled substance, it will be available by prescription only. The twice-daily pill will come in strengths of 50, 100, 150, 200, and 250 mg.
Janssen has listed certain cautions about the drug, including the potential for abuse because of the drug’s opioid nature, the possibility of life-threatening respiratory depression if the drug is ingested improperly (such as crushing the pill so that its extended-release capability is destroyed), and potential bad interactions with alcohol.
Categories: , Diabetes, Diabetes Health, Diabetes Medication, Diabetic, Peripheral Neuropathy, Research, USDA
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.

Comments
sounds good but does it really work when will it be on the market soon i hope
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register...
Register your Diabetes Health Username here.
Have Your Say...